Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Correlation of Target Molecule Expression and Overall Response in Refractory Cutaneous T-Cell Lymphoma Patients Dosed with Mogamulizumab (KW-0761), a Monoclonal Antibody Directed Against CC Chemokine Receptor Type 4 (CCR4)

Madeleine Duvic, MD, Lauren Pinter-Brown, Francine Foss, MD, Lubomir Sokol, MD, PhD, Jeffrey Jorgensen, MD, PhD, Xiao Ni, MD, PhD, Pramoda Challagundla, MS, Meghali Goswami, BS, Karen Dwyer, Nehal Mohamed, PhD, Youn H Kim, MD

Blood (2012) 120 (21): 3697.

https://doi.org/10.1182/blood.V120.21.3697.3697

Published: 2012

Journal Articles

Phase II Study of Sequential Therapy with Cladribine Followed by an Extended Course Rituximab in Patients with Hairy Cell Leukemia

Farhad Ravandi, MD, Jeffrey Jorgensen, MD, PhD, Susan O'Brien, MD, Deborah A Thomas, MD, Stefan Faderl, MD, Sergernne York, RN, Jan A. Burger, MD, PhD, Alessandra Ferrajoli, MD, Sherry Pierce, RN, BS, Michael Keating, MD, Hagop Kantarjian, MD

Blood (2010) 116 (21): 2458.

https://doi.org/10.1182/blood.V116.21.2458.2458

Published: 2010

Journal Articles

Results of a Phase 1/2 Study for KW-0761, a Monoclonal Antibody Directed Against CC Chemokine Receptor Type 4 (CCR4), In CTCL Patients

Madeleine Duvic, MD, Lauren Pinter-Brown, MD, Francine M Foss, MD, Lubomir Sokol, MD, PhD, Jeffrey Jorgensen, MD, PhD, George L Spitalny, PhD, Youn H. Kim, MD

Blood (2010) 116 (21): 962.

https://doi.org/10.1182/blood.V116.21.962.962

Published: 2010

Journal Articles

Significance of Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) In Adults with De Novo Acute Lymphoblastic Leukemia (ALL) After Therapy with the Modified Hyper-CVAD Regimen

Deborah A. Thomas, MD, Susan O'Brien, MD, Jeffrey Jorgensen, MD, PhD, Sa A. Wang, MD, Stefan Faderl, MD, William G. Wierda, MD, PhD, Rebecca Garris, BA, Michael Andreeff, MD, PhD, Jorge E. Cortes, MD, Hagop Kantarjian, MD

Blood (2010) 116 (21): 2145.

https://doi.org/10.1182/blood.V116.21.2145.2145

Published: 2010

Journal Articles

Dynamics of Minimal Residual Leukemia After Combinations of the HyperCVAD Regimen with Imatinib or Dasatinib In Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

Farhad Ravandi, MD, Deborah A Thomas, MD, Susan O'Brien, MD, Stefan Faderl, MD, Jeffrey Jorgensen, MD, PhD, Rajyalakshmi Luthra, PhD, Dan Jones, MD, PhD, Rebecca Garris, BA, Jorge E. Cortes, MD, Hagop Kantarjian, MD

Blood (2010) 116 (21): 2127.

https://doi.org/10.1182/blood.V116.21.2127.2127

Published: 2010

Journal Articles

Phase II Study of Combination of the HyperCVAD Regimen with Dasatinib in Patients with Philadelphia Chromosome (Ph) or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).

Farhad Ravandi, MD, Deborah Thomas, MD, Hagop Kantarjian, MD, Stefan Faderl, MD, Charles Koller, MD, Devri Brown, Rebecca Garris, Gautam Borthakur, MD, Jan Burger, MD, Partow Kebriaei, MD, Jeffrey Jorgensen, MD, Dan Jones, MD, Jorge Cortes, MD, Susan O’Brien, MD

Blood (2007) 110 (11): 2814.

https://doi.org/10.1182/blood.V110.11.2814.2814

Published: 2007

Journal Articles

Complete Eradication of Minimal Residual Disease (MRD) in Patients with Hairy Cell Leukemia (HCL) after Cladribine (2CDA) Followed by an Extended Course of Rituximab.

Farhad Ravandi-Kashani, MD, Susan O’Brien, MD, Keating Michael, MD, Dan Jones, MD, Stefan Faderl, MD, Alessandra Ferrajoli, MD, William Wierda, MD, Shirley Odinga, Sherry Pierce, Charles Koller, MD, Srdan Verstovsek, MD, Jeffrey Jorgensen, MD, Hagop Kantarjian, MD

Blood (2005) 106 (11): 3258.

https://doi.org/10.1182/blood.V106.11.3258.3258

Published: 2005

NARROW

Correlation of Target Molecule Expression and Overall Response in Refractory Cutaneous T-Cell Lymphoma Patients Dosed with Mogamulizumab (KW-0761), a Monoclonal Antibody Directed Against CC Chemokine Receptor Type 4 (CCR4)

Phase II Study of Sequential Therapy with Cladribine Followed by an Extended Course Rituximab in Patients with Hairy Cell Leukemia

Results of a Phase 1/2 Study for KW-0761, a Monoclonal Antibody Directed Against CC Chemokine Receptor Type 4 (CCR4), In CTCL Patients

Significance of Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) In Adults with De Novo Acute Lymphoblastic Leukemia (ALL) After Therapy with the Modified Hyper-CVAD Regimen

Dynamics of Minimal Residual Leukemia After Combinations of the HyperCVAD Regimen with Imatinib or Dasatinib In Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

Phase II Study of Combination of the HyperCVAD Regimen with Dasatinib in Patients with Philadelphia Chromosome (Ph) or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).

Complete Eradication of Minimal Residual Disease (MRD) in Patients with Hairy Cell Leukemia (HCL) after Cladribine (2CDA) Followed by an Extended Course of Rituximab.

Email alerts

ASH Publications

American Society of Hematology

Correlation of Target Molecule Expression and Overall Response in Refractory Cutaneous T-Cell Lymphoma Patients Dosed with Mogamulizumab (KW-0761), a Monoclonal Antibody Directed Against CC Chemokine Receptor Type 4 (CCR4)

Phase II Study of Sequential Therapy with Cladribine Followed by an Extended Course Rituximab in Patients with Hairy Cell Leukemia

Results of a Phase 1/2 Study for KW-0761, a Monoclonal Antibody Directed Against CC Chemokine Receptor Type 4 (CCR4), In CTCL Patients

Significance of Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) In Adults with De Novo Acute Lymphoblastic Leukemia (ALL) After Therapy with the Modified Hyper-CVAD Regimen

Dynamics of Minimal Residual Leukemia After Combinations of the HyperCVAD Regimen with Imatinib or Dasatinib In Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

Phase II Study of Combination of the HyperCVAD Regimen with Dasatinib in Patients with Philadelphia Chromosome (Ph) or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).

Complete Eradication of Minimal Residual Disease (MRD) in Patients with Hairy Cell Leukemia (HCL) after Cladribine (2CDA) Followed by an Extended Course of Rituximab.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only